Viking Therapeutics, Inc.
VKTX
Classificação em ações
#4567
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Preço da ação
$26.38
Valor de mercado
$3.35B
Variação (1 dia)
-1.23%
Variação (1 ano)
-20.01%
País
US
Negociar Viking Therapeutics, Inc. (VKTX)
Categoria
Healthcare
Rácio P/B de Viking Therapeutics, Inc. (VKTX)
Rácio P/B em 2026 TTM: 0
De acordo com os relatórios financeiros mais recentes e o preço das ações da Viking Therapeutics, Inc., o rácio P/B atual (TTM) é 0. No final de 2026, o rácio P/B era 0.
Histórico do rácio P/B da Viking Therapeutics, Inc. de 2026 a 2026
Rácio P/B no final de cada ano
| Ano | Rácio P/B | Alterar |
|---|---|---|
| Não há dados suficientes para as datas fornecidas. | ||
Rácio P/B de empresas semelhantes ou concorrentes
| Empresa | Rácio P/B | Diferença do rácio P/B | País |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| 6.1824 | - |
NL
|
|
| - | - |
CH
|
